Dan Bradbury is a life sciences executive with more than 35 years of experience creating and implementing strategies that transform businesses, bring novel medicines to market, and maximize shareholder value. He is the Executive Chairman and Co-Founder of Equillium, Inc. and served as the Chief Executive Officer until January 2020. Bradbury is also the Managing Member of BioBrit, LLC, a Life Sciences Consulting and Investment Firm. Equillium, Inc. and BioBrit, LLC are based in La Jolla, CA.
He is the former President, Chief Executive Officer, and Director of Amylin Pharmaceuticals, a biopharmaceutical company based in San Diego, CA, focused on metabolic diseases. He served as Amylin’s Chief Executive Officer from March 2007 until its acquisition by Bristol-Myers Squibb Company in August 2012. Before joining Amylin, he worked in marketing and sales roles for 10 years at SmithKline Beecham Pharmaceuticals.
Bradbury serves on the board of directors of Biocon Limited (NSE: BIOCON), Castle Biosciences, Inc. (NASDAQ: CSTL), Equillium, Inc. (NASDAQ: EQ), Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), and several private companies and philanthropic organizations.
Bradbury earned a Bachelor of Pharmacy degree from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education in the United Kingdom.